CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company, has announced that the first patient has been successfully treated with its proprietary irinotecan ChemoSeed® implant as part of a registration-grade Phase II clinical trial in glioblastoma. The procedure was carried out at University Hospitals Birmingham NHS Foundation Trust, the company's lead NHS clinical trial site, on 16 November 2026. The milestone marks the commencement of clinical data generation for CRISM's lead oncology asset and is a material step towards establishing the safety and efficacy profile of ChemoSeed® in a disease the company describes as having significant unmet medical need.

Key Points

  • CRISM Therapeutics Corporation (AIM: CRTX)
  • First patient successfully treated with irinotecan ChemoSeed® implant in a registration-grade Phase II glioblastoma trial
  • Procedure completed at University Hospitals Birmingham NHS Foundation Trust with no reported procedural complications; patient remained clinically stable post-operatively with no seizures reported
  • Investors should watch for further updates on patient assessments and ongoing recruitment progress into the Phase II study

ChemoSeed® Implanted at University Hospitals Birmingham in Recurrent Glioblastoma Surgery

The procedure involved implantation of ChemoSeed® into the tumour resection cavity following surgical removal of recurrent glioblastoma. The announcement states the surgical procedure was completed successfully, with the implant placed as planned and no procedural complications reported. The patient remained clinically stable during the initial post-operative period, with no seizures reported following surgery. The patient will continue to undergo scheduled post-operative clinical and imaging assessments in accordance with the study protocol, and CRISM has stated it will provide further updates as recruitment progresses and assessments are reviewed.

How ChemoSeed® Bypasses the Blood-Brain Barrier to Target Glioblastoma

ChemoSeed® is designed to be implanted directly into a tumour or the resection margin following tumour removal, enabling therapeutic concentrations of chemotherapy drugs to reach deep-seated tumour tissue. In glioblastoma, the technology bypasses the blood-brain barrier — a significant obstacle that prevents many systemic treatments from reaching the tumour effectively. The irinotecan formulation is CRISM's lead asset, and the Phase II trial is registration-grade, meaning data generated is intended to support a potential regulatory pathway. CRISM is also developing a docetaxel ChemoSeed® formulation for advanced prostate cancer, with pre-clinical data referenced in the announcement showing a 58% reduction in tumour volume compared to systemic standard-of-care.

CSO Professor McConville and Medical Advisor Professor Cruickshank Comment on the Milestone

Professor Christopher McConville, Chief Scientific Officer, described the first patient treatment as "a landmark achievement" and "the culmination of many years of research, development and clinical preparation," according to the announcement. Medical Advisor Professor Garth Cruickshank, who was present during the procedure, stated that witnessing the first implantation was "an important moment" and indicated ChemoSeed® could be incorporated into neurosurgical practice in a "straightforward and well-tolerated manner." Both noted that further clinical follow-up will be essential to evaluate safety and tolerability before broader conclusions can be drawn.

Phase II Recruitment Continues as CRISM Advances Towards Clinical Evidence Package

With the first patient treated, CRISM's immediate focus turns to monitoring the patient's recovery and continuing recruitment at University Hospitals Birmingham. As a clinical-stage company, CRISM does not yet generate product revenues, and progress in this trial represents a primary value-creation pathway for the business. The registration-grade nature of the Phase II study means that trial outcomes carry direct regulatory significance. Investors may be watching recruitment pace and forthcoming safety and tolerability data as key indicators of whether ChemoSeed® can progress towards a potential regulatory submission.